Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Kobayashi S, Fukushima T, Ueno M, Chuma M, Numata K, Tsuruya K, Arase Y, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Uojima H, Hidaka H, Kusano C, Morimoto M, Maeda S. Kobayashi S, et al. Among authors: hattori n. Liver Int. 2024 Jun;44(6):1343-1350. doi: 10.1111/liv.15825. Epub 2024 Mar 4. Liver Int. 2024. PMID: 38436529
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.
Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Chuma M, et al. Among authors: hattori n. Hepatol Res. 2022 Mar;52(3):269-280. doi: 10.1111/hepr.13732. Epub 2021 Nov 30. Hepatol Res. 2022. PMID: 34761470
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S. Fukushima T, et al. Among authors: hattori n. Oncologist. 2023 Jul 5;28(7):e526-e533. doi: 10.1093/oncolo/oyad090. Oncologist. 2023. PMID: 37023703 Free PMC article.
Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy.
Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A, Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C. Uojima H, et al. Among authors: hattori n. Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):865-873. doi: 10.1097/MEG.0000000000002581. Epub 2023 Jun 6. Eur J Gastroenterol Hepatol. 2023. PMID: 37395239
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.
Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Chuma M, et al. Among authors: hattori n. Cancers (Basel). 2020 Jan 26;12(2):293. doi: 10.3390/cancers12020293. Cancers (Basel). 2020. PMID: 31991869 Free PMC article.
Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.
Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S. Ogushi K, et al. Among authors: hattori n. Clin Exp Gastroenterol. 2020 Oct 1;13:385-396. doi: 10.2147/CEG.S256691. eCollection 2020. Clin Exp Gastroenterol. 2020. PMID: 33061517 Free PMC article.
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.
Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S. Chuma M, et al. Among authors: hattori n. Hepatol Res. 2021 Feb;51(2):201-215. doi: 10.1111/hepr.13592. Epub 2021 Jan 5. Hepatol Res. 2021. PMID: 33270323
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S. Fukushima T, et al. Among authors: hattori n. JGH Open. 2021 Dec 17;6(1):29-35. doi: 10.1002/jgh3.12691. eCollection 2022 Jan. JGH Open. 2021. PMID: 35071785 Free PMC article.
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M. Kobayashi S, et al. Among authors: hattori n. BMC Cancer. 2022 May 7;22(1):517. doi: 10.1186/s12885-022-09625-x. BMC Cancer. 2022. PMID: 35525913 Free PMC article.
2,465 results